Grapin M, et al. - In luminal/Human Epidermal growth factor Receptor 2 (HER2) negative subtypes of breast cancer, researchers identified breast and tumor ¹⁸Fluoro-deoxy-glucose (¹⁸F-FDG) PET-CT scan imaging features for the early prediction of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC). In patients with Luminal/HER2 negative breast cancer, the combination of tumor and mammary gland imaging at baseline and after the first cycle of NAC, obtained with ¹⁸F-FDG PET-CT, may allow the doctor to assess the probability of BCS.